Scarica l'app Stockscreener
9.15
5.90%
0.51
Pre-mercato:
9.15
Cervomed Inc Borsa (CRVO) Ultime notizie
What Will CervoMed Inc (NASDAQ: CRVO) Be Like In 2025 - Stocksregister
CervoMed Inc. Announces Executive Appointments and Officer Departure By Investing.com - Investing.com South Africa
CervoMed Announces Executive Appointments and Changes - MSN
CervoMed Inc. Announces Executive Appointments and Officer Departure - Investing.com Australia
CervoMed (CRVO) to Present Key Findings on Dementia Drug at Inte - GuruFocus
CervoMed (CRVO) Reports Positive Phase 2b Results for Neflamapim - GuruFocus
CervoMed Reports Positive Phase 2b Trial Results - TipRanks
Brokerages Set CervoMed Inc. (NASDAQ:CRVO) Price Target at $27.50 - Defense World
CervoMed To Present Phase 2b Data On Neflamapimod's Impact On DLB At AD/PD 2025 - Nasdaq
CervoMed to present results on Phase 2b RewinD-LB study - TipRanks
Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025 - GlobeNewswire
CervoMed Inc. to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD 2025 - marketscreener.com
Virtu Financial LLC Invests $26,000 in CervoMed Inc. (NASDAQ:CRVO) - Defense World
Biotech Stocks Q1 2025 Recap: Winners And Underperformers - Seeking Alpha
CervoMed (CRVO) Projected to Post Quarterly Earnings on Friday - Defense World
FY2025 EPS Estimates for CervoMed Lowered by Chardan Capital - Defense World
CervoMed (NASDAQ:CRVO) Given Buy Rating at D. Boral Capital - Defense World
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
CervoMed Announces Oral Presentation at 19th International - GlobeNewswire
CervoMed Inc. to Present Findings on Neflamapimod in Dementia with Lewy Bodies at AP/PD™ Conference 2025 - Nasdaq
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™) - The Manila Times
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™) - TradingView
New Clinical Data: CervoMed's Breakthrough Dementia Drug Results Revealed at Global Conference - Stock Titan
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats - Seeking Alpha
CervoMed Stock: Extension Study Data In Dementia Is Potentially Exciting, With Caveats - Seeking Alpha
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Brokers Offer Predictions for CervoMed Q1 Earnings - Defense World
Q1 Earnings Forecast for CervoMed Issued By Roth Capital - Defense World
Is CervoMed Inc. (CRVO) Among the Best Short Squeeze Stocks to Buy According to Analysts? - Insider Monkey
CervoMed reports FY24 EPS ($2.02), consensus ($1.85) - MSN
CervoMed Inc (CRVO) Reports Q4 Net Loss of $16.3 Million, Grant Revenue at $9.7 Million - GuruFocus.com
Roth Mkm Issues Positive Forecast for CervoMed (NASDAQ:CRVO) Stock Price - Defense World
CervoMed (NASDAQ:CRVO) Given New $21.00 Price Target at Canaccord Genuity Group - Defense World
Best Biotech Stocks To Watch Now – March 17th - Defense World
10 Best Short Squeeze Stocks To Buy According to Analysts - Insider Monkey
CervoMed price target raised to $20 from $15 at Roth MKM - TipRanks
Following A Monumental March, Can CRVO Keep The Rally Going In April? - RTTNews
CervoMed sees cash runway into mid-2026 - MSN
CervoMed Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
CervoMed price target raised to $21 from $12 at Canaccord - TipRanks
CervoMed Inc. (CRVO): The Best Short-Term Stock to Buy Right Now - Insider Monkey
Cervomed Inc. Faces Financial Hurdles Due to Regulatory Restrictions on Public Float - TipRanks
Small Cap Stocks To Watch NowMarch 13th - MarketBeat
Peering Into CervoMed's Recent Short Interest - Benzinga
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):